Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 27, 2026, 5:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–20 of 20 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Peripheral Endovascular Intervention Clear all
Terminated Phase 3 Interventional Results available

The Value of Screening for HPR in Patients Undergoing Lower Extremity Arterial Endovascular Interventions

NCT04007055
View directory record Official record
Conditions
Peripheral Artery Disease, Clopidogrel, Poor Metabolism of, Peripheral Vascular Disease, Artery Disease, Peripheral Arterial Occlusive Disease
Interventions
Point of care screening for HPR, Ticagrelor 90mg
Diagnostic Test · Drug
Lead sponsor
Marissa Jarosinski
Other
Eligibility
18 Years to 90 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Jun 27, 2026, 5:00 PM EDT
Completed Phase 2 Interventional

Safety Study of UT-15C SR (Oral Treprostinil) in Patients Undergoing a Lower Limb Endovascular Procedure

NCT00651885
View directory record Official record
Conditions
Critical Limb Ischemia
Interventions
treprostinil dienthanolmine sustained release, Placebo
Drug
Lead sponsor
Ochsner Health System
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Apr 23, 2023 · Synced Jun 27, 2026, 5:00 PM EDT
Recruiting Phase 4 Interventional

Vascular Trial Associated Registry Pilot

NCT07076082
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Clopidogrel (Plavix) Pharmacogenetic Test Reagents
Drug
Lead sponsor
Corewell Health West
Other
Eligibility
45 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Detroit, Michigan • Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Jun 27, 2026, 5:00 PM EDT
Completed Not applicable Interventional

The Use of Fish Oil to Reduce Inflammation Caused by a Peripheral Vascular Intervention

NCT02096757
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Pro-Omega, Pro-Omega Placebo
Dietary Supplement · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
40 Years to 90 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 17, 2020 · Synced Jun 27, 2026, 5:00 PM EDT
Terminated Phase 3 Interventional Results available

ENDOvascular Interventions With AngioMAX: The ENDOMAX Trial

NCT01913483
View directory record Official record
Conditions
Peripheral Endovascular Interventions, Bleeding
Interventions
Bivalirudin, Unfractionated Heparin
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
732 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
39
States / cities
Hot Springs, Arkansas • Stanford, California • Clearwater, Florida + 31 more
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Jun 27, 2026, 5:00 PM EDT
Completed Phase 2 Interventional Results available

Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents

NCT01319812
View directory record Official record
Conditions
Peripheral Artery Disease, Peripheral Vascular Disease
Interventions
Astron Stents, Pulsar Stents
Device
Lead sponsor
Biotronik, Inc.
Industry
Eligibility
18 Years and older
Enrollment
463 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
33
States / cities
Fremont, California • New Haven, Connecticut • Washington D.C., District of Columbia + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2019 · Synced Jun 27, 2026, 5:00 PM EDT
Completed No phase listed Observational

Outpatient Office Based Endovascular Procedures

NCT04054440
View directory record Official record
Conditions
Chronic Venous Insufficiency, Peripheral Arterial Disease, Dialysis Access Malfunction, Arterio-venous Fistula, Thoracic Outlet Syndrome, Vertebral Artery Insufficiency, Varicose Veins
Interventions
Not listed
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years and older
Enrollment
26,000 participants
Timeline
2014 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Jun 27, 2026, 5:00 PM EDT
Completed No phase listed Observational Results available

Observational Study to Evaluate PAD Treatment Clinical and Economic Outcomes

NCT01855412
View directory record Official record
Conditions
Peripheral Arterial Occlusive Disease
Interventions
PAD endovascular treatments
Other
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
1,204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
52
States / cities
Gilbert, Arizona • Glendale, Arizona • Phoenix, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2023 · Synced Jun 27, 2026, 5:00 PM EDT
Withdrawn Phase 3 Interventional

Short vs Long Duration Dual Antiplatelet Therapy in Patients Undergoing Lower Extremity Endovascular Revascularization

NCT02433587
View directory record Official record
Conditions
Peripheral Arterial Disease, Endovascular Procedures
Interventions
Aspirin, Clopidogrel
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 6, 2019 · Synced Jun 27, 2026, 5:00 PM EDT
Recruiting Phase 4 Interventional

Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention

NCT06909565
View directory record Official record
Conditions
Percutaneous Coronary Intervention, Peripheral Endovascular Intervention
Interventions
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, Normal Saline (Placebo)
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
6,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
103
States / cities
Alexander City, Alabama • Birmingham, Alabama • Huntsville, Alabama + 93 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Jun 27, 2026, 5:00 PM EDT
Not listed No phase listed Observational

Hyperspectral Imaging Pre and Post Endovascular Intervention

NCT00768495
View directory record Official record
Conditions
Chronic Limb Ischemia, Non-Healing Ulcers
Interventions
Not listed
Lead sponsor
HyperMed
Industry
Eligibility
50 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 3, 2009 · Synced Jun 27, 2026, 5:00 PM EDT
Completed No phase listed Observational

Angio-Seal Evolution Device Registry

NCT00817349
View directory record Official record
Conditions
Peripheral Vascular Disease, Coronary Artery Disease, Peripheral Artery Disease, Arterial Occlusive Disease, Coronary Heart Disease
Interventions
Not listed
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
1,004 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
10
States / cities
Los Angeles, California • Ypsilanti, Michigan • Camden, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2019 · Synced Jun 27, 2026, 5:00 PM EDT
Completed Phase 2 Interventional Results available

Edoxaban in Peripheral Arterial Disease

NCT01802775
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
edoxaban, Clopidogrel, Aspirin
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
26
States / cities
Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 23 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2019 · Synced Jun 27, 2026, 5:00 PM EDT
Completed Not applicable Interventional

Assessment of Clin. Capabilities of LIBERTY® Endovascular Robotic System's Performance & Safety in Periph. Vasc. Interv.

NCT06141694
View directory record Official record
Conditions
Peripheral Vascular Interventions
Interventions
The LIBERTY® Robotic System
Device
Lead sponsor
Microbot Medical, INC
Industry
Eligibility
22 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
3
States / cities
Miami, Florida • Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Jun 27, 2026, 5:00 PM EDT
Recruiting No phase listed Observational

Multi-Center Registry for Peripheral Arterial Disease Interventions and Outcomes

NCT01904851
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Not listed
Lead sponsor
Baylor Research Institute
Other
Eligibility
Not listed
Enrollment
14,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2033
U.S. locations
24
States / cities
Little Rock, Arkansas • Denver, Colorado • Atlanta, Georgia + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Jun 27, 2026, 5:00 PM EDT
Completed No phase listed Observational Results available

Post-Market Registry of AURYON Atherectomy Device in Subjects Affected With Infrainguinal Peripheral Artery Disease

NCT04229563
View directory record Official record
Conditions
Infrainguinal Peripheral Artery Disease, Peripheral Arterial Disease, PAD
Interventions
AURYON Atherectomy System
Device
Lead sponsor
Angiodynamics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
10
States / cities
Scottsdale, Arizona • Tucson, Arizona • Davenport, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Jun 27, 2026, 5:00 PM EDT
Not listed No phase listed Observational

OEIS Outcome Data Registry

NCT03058913
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Not listed
Lead sponsor
Outpatient Endovascular and Interventional Society
Other
Eligibility
18 Years and older
Enrollment
600,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Hoffman Estates, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 27, 2022 · Synced Jun 27, 2026, 5:00 PM EDT
Completed Phase 4 Interventional Results available

Effectiveness of Intensive Lipid Modification Medication in Preventing the Progression of Peripheral Arterial Disease (The ELIMIT Study)

NCT00687076
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Ezetimibe, Niaspan, Statin therapy, Standard care, Aspirin, Clopidogrel, Placebo Niaspan, Placebo Ezetimibe, Percutaneous transluminal angioplasty (PTA)
Drug · Behavioral · Procedure
Lead sponsor
Baylor College of Medicine
Other
Eligibility
40 Years to 80 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Jun 27, 2026, 5:00 PM EDT
Recruiting Not applicable Interventional

The Golazo® Peripheral Atherectomy System for a Safe and Effective Atherectomy (GREAT Trial)

NCT06321575
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Golazo® Peripheral Atherectomy System (Golazo® Peripheral AS)
Device
Lead sponsor
Avantec Vascular
Industry
Eligibility
18 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
20
States / cities
Scottsdale, Arizona • Merced, California • Fort Lauderdale, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jun 27, 2026, 5:00 PM EDT
Completed No phase listed Observational Results available

VASCADE ANTEGRADE-PVD Post-Market Registry

NCT02948257
View directory record Official record
Conditions
Surgical Wound
Interventions
Cardiva Medical VASCADE VCS
Device
Lead sponsor
Cardiva Medical, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
5
States / cities
Houma, Louisiana • Tupelo, Mississippi • Wilmington, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2020 · Synced Jun 27, 2026, 5:00 PM EDT